Inside information: Orion to receive EUR 180 million milestone and updates full-year outlook for 2025

Core Viewpoint - Orion Corporation will receive a milestone payment of EUR 180 million related to Nubeqa® sales, impacting its financial outlook for 2025 [1] Financial Outlook Update - The new full-year outlook for 2025 estimates net sales to be between EUR 1,820 million and EUR 1,900 million [2] - Operating profit for 2025 is estimated to be between EUR 590 million and EUR 670 million [2] Previous Financial Outlook - The previous full-year outlook for 2025 estimated net sales to be between EUR 1,640 million and EUR 1,720 million [3] - Operating profit was estimated to be between EUR 410 million and EUR 490 million [3] Company Overview - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on human and veterinary pharmaceuticals [3] - The company has a diverse portfolio including proprietary and generic medicines, with core therapy areas in oncology and pain [3] - In 2024, Orion's net sales were EUR 1,542 million, employing approximately 3,700 professionals globally [3]